| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000017850 |
| Receipt No. | R000020685 |
| Official scientific title of the study | Study of late renal failure evaluation by cystatin C for pediatric kidney tumor patients |
| Date of disclosure of the study information | 2015/06/09 |
| Last modified on | 2016/06/09 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Study of late renal failure evaluation by cystatin C for pediatric kidney tumor patients | |
| Title of the study (Brief title) | Study of late renal failure evaluation by cystatin C for pediatric kidney tumor patients | |
| Region |
|
|
| Condition | |||
| Condition | kidney tumor | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Purpose is whether serum cystatin C can be detected at an early stage renal failure in pediatric kidney tumor patients during and after treatment |
| Basic objectives2 | Others |
| Basic objectives -Others | examine the patients with renal failure after treatment of childhood renal tumor |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Whether the course of the subsequent renal failure of cases that showed abnormal rates of serum cystatin C. |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who participated in the clinical trial of JWiTS study | |||
| Key exclusion criteria | Other than those above | |||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Hajime Hosoi |
| Organization | Graduate School of Medical Science
Kyoto Prefectural University of Medicine |
| Division name | Pediatrics |
| Address | Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, JAPAN |
| TEL | 0752515571 |
| hhosoi@koto.kpu-m.ac.jp | |
| Public contact | |
| Name of contact person | Tomoko Iehara |
| Organization | Graduate School of Medical Science Kyoto Prefectural University of Medicine |
| Division name | Pediatrics |
| Address | Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, JAPAN |
| TEL | 0752515571 |
| Homepage URL | |
| iehara@koto.kpu-m.ac.jp | |
| Sponsor | |
| Institute | JWiTS |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development, AMED |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | practical research |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000020685 |